Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure
July 7, 2025Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure
HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
T-cell therapy – the evolution of cancer treatments
July 7, 2025CERo therapeutics, Cancer, T cell, immunotherapy
The current forms of immunotherapy, how T cell therapy works and what the future holds
Purpose and people: the enduring power of brand and the evolution of employer identity
July 7, 2025Branding, Business Services, Corporate Branding, Medical Communications, Sales and Marketing AstraZeneca, Identity, Inclusion, The Caffeine Partnership, benenden health, branding
Two decades ago, terms like purpose and people were rarely at the forefront of branding conversations. The focus was on …
The Problem of Endometriosis in the UK
July 7, 2025Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology
When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?
Five facts about UV exposure and sun safety
July 7, 2025Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …
LEO Pharma appoints Helle Hedegaard Juhl as EVP of global people & corporate affairs
July 7, 2025Manufacturing and Production Dermatology, Helle Hedegaard Juhl, LEO Pharma, Skin, dermatology
Danish dermatology company, LEO Pharma, announced the appointment of new executive vice president (EVP) of global people and corporate affairs, …
Mallia strengthens its advisory board as it accelerates hair loss treatment
July 7, 2025Manufacturing and Production Dermatology, Skin, biopharma, dermatology, hair loss, mallia
German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
July 4, 2025Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
The quiet crisis: why medicines operations matter more than ever in the ICB era
July 4, 2025Business Services, Market Access Gateway to Local Adoption, Integrated Care Board, NHS, Primary Care Networks, Visions4Health
In the second of the Gateway to Local Access series, Vision4Health caught up with Dr Graham Duce, ICB GP Prescribing …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Nick Challoner appointed CEO of Ingenza to drive further growth
July 4, 2025Business Services, Manufacturing and Production CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president
Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
July 3, 2025Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …
Carthera receives EMA endorsement for orphan medical device status of SonoCloud
July 2, 2025Medical Communications, Research and Development Brain disorders, Breakthough Device Designation, CE marking, Carthera, Devices, European Medicines Agency (EMA), Food and Drug Administration, Forfait Innovation Status, Neurology, Orphan Medical Device Status, ultrasound imaging
French biotech company Carthera has announced that its SonoCloud system has been granted orphan medical device status by the European …
SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant
July 1, 2025Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine
SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
July 1, 2025Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
June 30, 2025Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
June 30, 2025Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …
Defining neighbourhood working: big picture or local lens?
June 27, 2025Business Services Gateway to Local Adoption, NHS England, neighbourhood working
In the first of the Gateway to Local Adoption series, Visions4Health caught up with Dr Nick Merrifield to discuss his views on …
Latest content
FibroFind appoints Lee Borthwick as CEO
